Literature DB >> 17584773

Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys.

Bradley A Wallace1, Keyoumars Ashkan, Claire E Heise, Kelly D Foote, Napoleon Torres, John Mitrofanis, Alim-Louis Benabid.   

Abstract

We have examined dopaminergic cell survival after alteration of the subthalamic nucleus (STN) in methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. The STN was lesioned with kainic acid (B series) or underwent deep brain stimulation (DBS) at high frequency (C series). In another series, MPTP-treated and non-MPTP-treated monkeys had no STN alteration (intact animals; A series). Animals were treated with MPTP either after (B1, C1) or before (B2, C2) STN alteration. We also explored the long-term ( approximately 7 months) effect of DBS in non-MPTP-treated monkeys (D series). Brains were aldehyde-fixed and processed for routine Nissl staining and tyrosine hydroxylase immunocytochemistry. Our results showed that there were significantly more (20-24%) dopaminergic cells in the substantia nigra pars compacta (SNc) of the MPTP-treated monkeys that had STN alteration, either with kainic acid lesion or DBS, compared to the non-MPTP-treated monkeys (intact animals). We suggest that this saving or neuroprotection was due to a reduction in glutamate excitotoxicity, as a result of the loss or reduction of the STN input to the SNc. Our results also showed that SNc cell number in the B1 and C1 series were very similar to those in the B2 and C2 series. In the cases that had long-term DBS of the STN (D series), there was no adverse impact on SNc cell number. In summary, these results indicated that STN alteration offered neuroprotection to dopaminergic cells that would normally die as part of the disease process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17584773     DOI: 10.1093/brain/awm137

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  64 in total

Review 1.  Mechanisms of deep brain stimulation.

Authors:  Todd M Herrington; Jennifer J Cheng; Emad N Eskandar
Journal:  J Neurophysiol       Date:  2015-10-28       Impact factor: 2.714

2.  Deep brain stimulation in Parkinson's disease.

Authors:  S J Groiss; L Wojtecki; M Südmeyer; A Schnitzler
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

Review 3.  What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors:  Rüdiger Hilker; Angelo Antonini; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

4.  Dissociation between time reproduction of actions and of intervals in patients with Parkinson's disease.

Authors:  Diana Maria Elena Torta; Lorys Castelli; Luca Latini-Corazzini; Alessandra Banche; Leonardo Lopiano; Giuliano Geminiani
Journal:  J Neurol       Date:  2010-03-30       Impact factor: 4.849

5.  Bilateral subthalamic stimulation impairs cognitive-motor performance in Parkinson's disease patients.

Authors:  Jay L Alberts; Claudia Voelcker-Rehage; Katie Hallahan; Megan Vitek; Rashi Bamzai; Jerrold L Vitek
Journal:  Brain       Date:  2008-10-07       Impact factor: 13.501

Review 6.  Mechanisms and targets of deep brain stimulation in movement disorders.

Authors:  Matthew D Johnson; Svjetlana Miocinovic; Cameron C McIntyre; Jerrold L Vitek
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 7.  Deep brain stimulation for Parkinson's disease.

Authors:  Patricia Limousin; Irene Martinez-Torres
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 8.  Insights into the mechanisms of deep brain stimulation.

Authors:  Keyoumars Ashkan; Priya Rogers; Hagai Bergman; Ismail Ughratdar
Journal:  Nat Rev Neurol       Date:  2017-07-28       Impact factor: 42.937

9.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors:  Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

Review 10.  Deep Brain Stimulation for Movement Disorders of Basal Ganglia Origin: Restoring Function or Functionality?

Authors:  Thomas Wichmann; Mahlon R DeLong
Journal:  Neurotherapeutics       Date:  2016-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.